Management ChangeMay 5, 2026, 06:13 AM
Sanofi Appoints Belén Garijo as Director and CEO
AI Summary
Sanofi announced that its shareholders approved all resolutions at the Annual General Meeting on April 29, 2026, including the appointment of Belén Garijo as a board member. In line with a prior Board decision, Ms. Garijo will assume her duties as Chief Executive Officer on May 1, 2026. The General Meeting also approved an ordinary annual dividend of 4.12 per share, payable on May 7, 2026. Additionally, the board mandates for Christophe Babule and Jean-Paul Kress were renewed, and Christel Heydemann was welcomed as an independent board member.
Key Highlights
- Belén Garijo appointed as Director and Chief Executive Officer of Sanofi, effective May 1, 2026.
- Shareholders approved all resolutions at the Annual General Meeting on April 29, 2026.
- An ordinary annual dividend of "4.12 per share was approved, payable on May 7, 2026.
- Christophe Babule and Jean-Paul Kress had their board mandates renewed.
- Christel Heydemann, CEO of Orange, was welcomed as an independent board member.
- The Board of Directors now comprises 16 members, with 79% independence and 57% women.
- Frédéric Oudéa appointed Chairman of the Appointments, Governance and CSR Committee.
- Belén Garijo appointed as a member of the Strategic Committee.
- Christel Heydemann appointed to the Appointments, Governance and CSR Committee and Compensation Committee.